Alphabet’s GV subsidiary was among the participants in the immunology drug development platform’s first publicly disclosed round.
US-based immunotherapy discovery technology developer Seismic Therapeutic formally launched yesterday with $101m in series A funding from investors including internet technology group Alphabet’s GV unit.
Venture capital firm Lightspeed Venture Partners led the round, which also featured Boxer Capital, Polaris Partners, Samsara BioCapital, angel investor Timothy Springer and the company’s founders and management team.
Seismic has built a machine learning-equipped biologics development platform dubbed Impact, which incorporates structural biology, protein engineering and translational immunology to help drug developers accelerate the…
